Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors

Area of Science:

• Oncology
• Immunotherapy
• Molecular Diagnostics

Background:

• Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are a heterogeneous group of cancers lacking targeted molecular therapies.
• The Programmed Cell Death Ligand-1 (PD-L1) pathway is a key target in cancer immunotherapy.
• Understanding PD-L1 expression is crucial for identifying patients who may benefit from immune checkpoint inhibitors.

Purpose of the Study:

• To investigate the PD-L1 expression profile across different organs affected by GEPNETs.
• To compare the sensitivity of conventional immunohistochemistry (IHC) with RNA expression analysis (RT-PCR) for PD-L1 detection.
• To identify GEPNET patients suitable for immune checkpoint-targeted therapy.

Main Methods:

• Retrospective collection of 59 surgically or endoscopically resected GEPNET tissues.
• Evaluation of PD-L1 protein expression using immunohistochemistry (IHC).
• Assessment of PD-L1 messenger RNA (mRNA) expression using real-time polymerase chain reaction (RT-PCR).

Main Results:

• PD-L1 expression was significantly associated with high-grade GEPNET classification (p=0.012).
• PD-L1 mRNA expression was higher in tumor tissues compared to normal tissues in the appendix, stomach, and small intestine.
• PD-L1 mRNA expression was notably higher in GEP carcinomas (p=0.0031), and RT-PCR demonstrated greater sensitivity than IHC.

Conclusions:

• Real-time polymerase chain reaction (RT-PCR) is a more sensitive method for detecting PD-L1 expression compared to conventional immunohistochemistry (IHC).
• This research provides foundational data for future immunotherapy studies in appendix, stomach, and small intestine neuroendocrine carcinomas.
• The findings highlight the potential of PD-L1 targeted therapies for specific GEPNET subtypes.